To date, all work concerning the use of temozolomide (TMZ) in combination with a PLK1 inhibitor has been in the context of primary grade IV glioblastoma, which rarely carries an IDH1 mutation [46–48]. This evidence concerns the gene PLK1 and glioblastoma.